Femasys Inc
FEMY0.812USD
-0.008-0.96%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
21.99MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Femasys Inc Unternehmen
Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Unternehmensinformationen
BörsenkürzelFEMY
Name des UnternehmensFemasys Inc
IPO-datumJun 18, 2021
CEOMs. Kathy Lee-Sepsick
Anzahl der mitarbeiter69
WertpapierartOrdinary Share
GeschäftsjahresendeJun 18
Addresse3950 Johns Creek Court
StadtSUWANEE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl30024
Telefon17705003910
Websitehttps://www.femasys.com/
BörsenkürzelFEMY
IPO-datumJun 18, 2021
CEOMs. Kathy Lee-Sepsick
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
384.31K
+9.80%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Independent Director
Independent Director
--
--
Mr. Daniel Currie
Mr. Daniel Currie
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
Ms. Christine Thomas
Ms. Christine Thomas
Chief Regulatory and Clinical Officer
Chief Regulatory and Clinical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
384.31K
+9.80%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
341.26K
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Jul 18
Aktualisiert: Fri, Jul 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Chernett (Jorey)
4.99%
Dauntless Investment Group, LLC
4.84%
Uzialko (Edward R Jr.)
3.74%
The Vanguard Group, Inc.
2.54%
CM Management, LLC
1.31%
Other
82.58%
Aktionäre
Aktionäre
Anteil
Chernett (Jorey)
4.99%
Dauntless Investment Group, LLC
4.84%
Uzialko (Edward R Jr.)
3.74%
The Vanguard Group, Inc.
2.54%
CM Management, LLC
1.31%
Other
82.58%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
10.52%
Investment Advisor
10.24%
Investment Advisor/Hedge Fund
1.26%
Hedge Fund
0.23%
Venture Capital
0.10%
Research Firm
0.09%
Bank and Trust
0.05%
Other
77.52%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
70
7.31M
22.48%
+821.23K
2025Q1
67
7.22M
24.70%
+706.34K
2024Q4
60
4.03M
17.61%
-312.38K
2024Q3
58
3.32M
14.71%
-994.98K
2024Q2
60
3.27M
14.50%
-951.60K
2024Q1
59
3.16M
17.88%
-1.13M
2023Q4
59
3.12M
17.80%
-765.84K
2023Q3
57
3.89M
25.74%
+6.18K
2023Q2
54
3.49M
25.26%
-520.59K
2023Q1
51
3.40M
28.73%
-4.68M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Chernett (Jorey)
1.62M
4.99%
+1.62M
--
Feb 19, 2025
Dauntless Investment Group, LLC
1.58M
4.84%
+145.30K
+10.16%
Mar 31, 2025
Uzialko (Edward R Jr.)
1.22M
3.74%
--
--
Apr 08, 2025
The Vanguard Group, Inc.
825.67K
2.54%
--
--
Mar 31, 2025
CM Management, LLC
425.00K
1.31%
--
--
Mar 31, 2025
Lee-Sepsick (Kathy)
384.31K
1.18%
+34.31K
+9.80%
Jun 02, 2025
Clear Creek Financial Management, LLC
270.37K
0.83%
+14.00K
+5.46%
Mar 31, 2025
Geode Capital Management, L.L.C.
245.51K
0.75%
+29.34K
+13.57%
Mar 31, 2025
Currie (Daniel Scott)
109.24K
0.34%
+19.61K
+21.88%
Jun 02, 2025
State Street Global Advisors (US)
56.37K
0.17%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
